Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part II scores over 4 years from the start of the trial.

Background: The PASADENA study is an ongoing Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of intravenous prasinezumab, administered every 4 weeks, in early-stage Parkinson’s disease (PD) [1]. During the double-blind study period, prasinezumab-treated individuals showed less progression of motor signs (MDS-UPDRS Part III) [1].

Method: In lack of a long-term placebo arm, we compared participants enrolled in the PASADENA open-label extension (OLE) to an external comparison arm derived from the Parkinson’s Progression Markers Initiative (PPMI) observational study [Table 1] [2].

Results: Both PASADENA delayed- (n=94) and early-start (n=177) groups showed a slower decline (less increase in score) on MDS-UPDRS Part III in OFF- and ON-state and on MDS-UPDRS Part II, compared to the PPMI external comparison (n=303) [Figure 1].

Conclusion: This exploratory analysis, which requires confirmation in further studies, suggests that prasinezumab might slow motor progression long-term in PD.

Table 1

Figure 1

References: [1] Pagano, G., et al. Trial of Prasinezumab in Early-Stage Parkinson’s Disease. N Engl J Med 387, 421-432 (2022).
[2] Marek, K., et al. The Parkinson’s progression markers initiative (PPMI) – establishing a PD biomarker cohort. Ann Clin Transl Neurol 5, 1460-1477 (2018)

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/effect-of-prasinezumab-on-parkinsons-disease-motor-progression-in-a-long-term-open-label-extension-of-the-pasadena-trial/